Acarbose

Acarbose is a complex oligosaccharide that acts as an inhibitor of alpha-glucosidase, an enzyme of the intestinal brush border, and it is marketed under names such as Glucobay and Precose ^[1][3]. It is derived from the precursor molecule valienamine produced by Actinoplanes soil bacteria, though it is manufactured on a large scale for pharmaceutical use ^[1]. As a diabetes medication it is taken with meals to reduce the postprandial spike in blood glucose, and it has been used both as a treatment for type 2 diabetes and to reduce progression from impaired glucose tolerance to diabetes ^[1][3].

By slowing the breakdown of starches and sugars, acarbose lowers and delays the absorption of glucose from the gut, which flattens after-meal blood sugar peaks and, over time, modestly lowers HbA1c ^[1][3]. Delivering more undigested carbohydrate to the lower intestine also increases production of the gut hormone GLP-1 and shifts the gut microbiota and short-chain fatty acid output, effects that have been linked to improvements in blood pressure, blood lipids, and cardiovascular markers ^[3]. Its most common side effects, flatulence and diarrhea, stem directly from this mechanism, as carbohydrate that escapes digestion is fermented by colonic bacteria; these effects tend to lessen with continued use ^[1].

In the last decade acarbose has become a prominent candidate calorie-restriction mimetic in aging research. In a large multi-site study by the National Institute on Aging's Interventions Testing Program, lifelong acarbose feeding extended the lifespan of genetically diverse mice, with a striking sex difference: median lifespan rose markedly in males and only modestly in females ^[2]. Reviews describe acarbose as achieving some of the metabolic benefits of calorie restriction without requiring reduced food intake, and interest in testing it for healthy aging in humans has grown ^[1][4]. Acarbose is an approved prescription drug rather than a dietary supplement, and its aging-related use remains investigational ^[1].

This is a prescription medicine. Its most common effects are digestive: flatulence, bloating, abdominal cramps, and diarrhea, which come from unabsorbed carbs fermenting in the gut and usually ease as the dose is raised slowly. On its own acarbose does not cause low blood sugar, but when combined with insulin or a sulfonylurea it can, and importantly a low must then be treated with glucose (dextrose) rather than table sugar, because acarbose blocks the breakdown of ordinary sugar. It is avoided in inflammatory bowel disease, bowel obstruction, and significant liver problems, and liver enzymes are sometimes monitored at higher doses.

The interaction worth knowing is not with a drug but with the sugar used to treat its consequence. Acarbose alone rarely causes hypoglycemia, but combined with a sulfonylurea or insulin it can, and because acarbose blocks the intestinal alpha-glucosidases that split sucrose into glucose and fructose, table sugar corrects that hypoglycemia poorly. Glucose or dextrose is the form that still raises blood sugar normally.

Anything that digests carbohydrate in the gut opposes the drug directly: pancreatic enzyme preparations containing amylase, and intestinal adsorbents such as activated charcoal, reduce its effect. Drugs that raise blood glucose, including corticosteroids, thiazides and thyroid hormone, work against it pharmacologically.

Digoxin data conflict. One crossover study found acarbose impaired digoxin absorption, lowering both AUC and peak concentration, while a later crossover study at ordinary therapeutic doses found no meaningful change.

Checking a whole stack? Run it through interactions + stacks.

Acarbose was discovered by researchers at Bayer, derived from fermentation products of soil bacteria of the genus Actinoplanes, and developed as an oral treatment for type 2 diabetes. It reached the market in the 1990s under names such as Glucobay and Precose, establishing a long clinical track record as an alpha-glucosidase inhibitor that blunts the post-meal rise in blood sugar. Because it acts within the gut to slow carbohydrate digestion rather than forcing insulin release, it earned a reputation as a well-characterized and comparatively gentle antidiabetic agent. More recently it has attracted fresh attention from aging researchers, who have studied it as a possible calorie-restriction mimetic after it repeatedly extended lifespan in mice.

Acarbose enjoys a solid, well-earned reputation as a decades-old prescription medicine with a transparent, mechanically intuitive action; it simply slows how fast dietary carbohydrate is broken down and absorbed. Diabetes clinicians know it well, and its safety profile is unusually well mapped. Its second act in longevity science has made it something of a favorite in that community, since it is one of the few interventions to reliably lengthen mouse lifespan in rigorous multi-site testing, an effect that was notably stronger in males. The honest framing is that the human longevity case is still inferential, and its most common effects, gas and bloating from carbohydrate reaching the colon, are a direct and predictable result of how it works.